Your browser doesn't support javascript.
loading
Quantifying prediction of pathogenicity for within-codon concordance (PM5) using 7541 functional classifications of BRCA1 and MSH2 missense variants.
Loong, Lucy; Cubuk, Cankut; Choi, Subin; Allen, Sophie; Torr, Beth; Garrett, Alice; Loveday, Chey; Durkie, Miranda; Callaway, Alison; Burghel, George J; Drummond, James; Robinson, Rachel; Berry, Ian R; Wallace, Andrew; Eccles, Diana M; Tischkowitz, Marc; Ellard, Sian; Ware, James S; Hanson, Helen; Turnbull, Clare.
Afiliación
  • Loong L; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, United Kingdom.
  • Cubuk C; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, United Kingdom.
  • Choi S; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, United Kingdom.
  • Allen S; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, United Kingdom.
  • Torr B; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, United Kingdom.
  • Garrett A; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, United Kingdom.
  • Loveday C; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, United Kingdom.
  • Durkie M; Sheffield Diagnostic Genetics Service, NHS North East and Yorkshire Genomic Laboratory Hub, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom.
  • Callaway A; Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, United Kingdom; Human Genetics and Genomic Medicine, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Burghel GJ; Manchester Centre for Genomic Medicine and North West Genomic Laboratory Hub, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
  • Drummond J; East Genomic Laboratory Hub, Cambridge University Hospitals Genomic Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
  • Robinson R; North East and Yorkshire Genomic Laboratory Hub, The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
  • Berry IR; Bristol Genetics Laboratory, Pathology Sciences, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom.
  • Wallace A; Manchester Centre for Genomic Medicine and North West Genomic Laboratory Hub, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
  • Eccles DM; Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Tischkowitz M; Department of Medical Genetics, NIHR Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom.
  • Ellard S; Department of Molecular Genetics, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom.
  • Ware JS; National Heart and Lung Institute, Faculty of Medicine, and MRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom; NIHR Royal Brompton Cardiovascular Research Centre, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
  • Hanson H; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, United Kingdom; Department of Clinical Genetics, St. George's University Hospitals NHS Foundation Trust, London, United Kingdom.
  • Turnbull C; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, United Kingdom; Cancer Genetics Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom. Electronic address: clare.turnbull@icr.ac.uk.
Genet Med ; 24(3): 552-563, 2022 03.
Article en En | MEDLINE | ID: mdl-34906453
PURPOSE: Conditions and thresholds applied for evidence weighting of within-codon concordance (PM5) for pathogenicity vary widely between laboratories and expert groups. Because of the sparseness of available clinical classifications, there is little evidence for variation in practice. METHODS: We used as a truthset 7541 dichotomous functional classifications of BRCA1 and MSH2, spanning 311 codons of BRCA1 and 918 codons of MSH2, generated from large-scale functional assays that have been shown to correlate excellently with clinical classifications. We assessed PM5 at 5 stringencies with incorporation of 8 in silico tools. For each analysis, we quantified a positive likelihood ratio (pLR, true positive rate/false positive rate), the predictive value of PM5-lookup in ClinVar compared with the functional truthset. RESULTS: pLR was 16.3 (10.6-24.9) for variants for which there was exactly 1 additional colocated deleterious variant on ClinVar, and the variant under examination was equally or more damaging when analyzed using BLOSUM62. pLR was 71.5 (37.8-135.3) for variants for which there were 2 or more colocated deleterious ClinVar variants, and the variant under examination was equally or more damaging than at least 1 colocated variant when analyzed using BLOSUM62. CONCLUSION: These analyses support the graded use of PM5, with potential to use it at higher evidence weighting where more stringent criteria are met.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Variación Genética / Mutación Missense Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Variación Genética / Mutación Missense Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido